Subscribe To
VYNT / Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery
VYNT News
By Proactive Investors
May 12, 2023
Vyant Bio to pursue listing on OTC Pink Open Market
Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist more_horizontal
By Proactive Investors
February 3, 2023
Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives
Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agree more_horizontal
By Proactive Investors
January 4, 2023
Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value
Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on more_horizontal
By Seeking Alpha
November 17, 2022
Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Office more_horizontal
By Proactive Investors
November 15, 2022
Vyant Bio in position to be fully funded through 2023 following sale of subsidiary, 3Q results show
Vyant Bio (NASDAQ:VYNT) Inc has reported its third-quarter financial results and announced it expects to be able to fund operations through to at leas more_horizontal
By Proactive Investors
November 3, 2022
Vyant Bio sells biotech branch vivoPharm to Reaction Biology for $5.5 million
Vyant Bio (NASDAQ:VYNT) Inc said it has closed a definitive agreement with Reaction Biology Corporation in the sale of its subsidiary vivoPharm LLC, a more_horizontal
By Proactive Investors
August 23, 2022
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next year
Vyant Bio (NASDAQ:VYNT) Inc revealed that it is advancing its repurposed drug candidate, VYNT-0126 to treat Rett Syndrome, into clinical trials early more_horizontal
By Seeking Alpha
August 22, 2022
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call Transcript
Vyant Bio, Inc. (NASDAQ:VYNT ) Q2 2022 Results Earnings Conference Call August 22, 2022 4:30 PM ET Company Participants Jay Roberts - President and Ch more_horizontal